Fi­bro­Gen re­ports third PhI­II fail­ure in two months, this time in id­io­path­ic pul­monary fi­bro­sis

Fi­bro­Gen’s pam­revlum­ab failed an­oth­er Phase III study — the biotech’s third late-stage miss in two months — and its shares plum­met­ed 76% be­fore Mon­day’s open­ing bell. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER